Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us

We are excited to present Genfit (OTC: GNFTF).

Full DD Report for GNFTF

Recent News from (OTC: GNFTF)

Genfit reports FY results
Genfit ( OTCPK:GNFTF ): FY EPS of -€1.88 Revenue of €6.86M (+1.2% Y/Y) Press Release More news on: Genfit, Earnings news and commentary,
Source: SeekingAlpha
Date: March, 13 2018 17:45
Premarket analyst action - healthcare
Cara Therapeutics (NASDAQ: CARA ) resumed with Buy rating and $22 (53% upside) price target at H.C. Wainwright. More news on: Cara Therapeutics Inc., Mirati Therapeutics, Inc., Fennec Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: March, 12 2018 08:38
Avisol's February Theme Of The Month: NASH, Its Causes, And Genfit Focus
In our previous article, we gave a brief introduction to the NASH space. We looked at the major players developing NASH therapies ( phase 2 and phase 3). We discussed the pathogenesis of NAFLD and NASH. Finally, we kicked off the series by looking at one of the leaders in the race to develop N...
Source: SeekingAlpha
Date: February, 07 2018 08:00
PPAR Agonists And NASH: The French - Genfit And Inventiva - Are Back In Town
Editor's note: Seeking Alpha is proud to welcome First Genesis Consulting as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Pro. Click here to find out more » A healt...
Source: SeekingAlpha
Date: February, 06 2018 13:52
Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept
We are kicking off our "Theme of the Month" series today, covering a themed topic for every month. For February, it's NASH (non-alcoholic steatohepatitis). In other months, we will take up diseases, conferences, or anything else that needs deep focus. For more details about the NASH schedule, ...
Source: SeekingAlpha
Date: February, 02 2018 12:03
The Science Behind Genfit's Elafibranor
In a recent note , we briefly discussed the two leading players in the NASH space: Genfit ( GNFTF ) and Intercept ( ICPT ). The note though did not dig deep into the science behind the two drug candidates, Genfit’s elafibranor and Intercept’s OCA. In this article, we will be foc...
Source: SeekingAlpha
Date: January, 29 2018 08:00
Intercept Vs. Genfit: Who Is Winning The NASH Race?
After Gilead’s ( GILD ) Hepatitis-C franchise met with phenomenal success and equally phenomenal decline, focus shifted to a new area in the liver space; non-alcoholic steatohepatitis or NASH as it is more commonly known now. NASH is the next stage of non-alcoholic fatty liver disease o...
Source: SeekingAlpha
Date: January, 08 2018 01:33
Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial
Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year...
Source: SeekingAlpha
Date: December, 30 2017 13:35
Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering
Content Analysis of coverage: REGN Stocks in the news: LLY, SNY, BLUE Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & An...
Source: SeekingAlpha
Date: December, 14 2017 04:07
Your Daily Pharma Scoop: Gilead Remains Long-Term Story, Argenx Rallies, Bluebird Data
Content Analysis of coverage Stocks in the news Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar TPT subscribers only Trade Idea of the Day Subscriber Questions & Answers Catalyst Ru...
Source: SeekingAlpha
Date: December, 12 2017 06:13


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Genfit (OTC: GNFTF)

Logo for Genfit (OTC: GNFTF)

Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.


Contact Information



Current Share Structure


    Daily Technical Chart for (OTC: GNFTF)

    Daily Technical Chart for (OTC: GNFTF)

    Stay tuned for daily updates and more on (OTC: GNFTF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: GNFTF)

    Do your DD and if you choose, be ready to go!


    The Research: All source information contained in this email is from the public sources mentioned below.



    Thank you

    The Subway Trader



    Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GNFTF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of GNFTF and does not buy, sell, or trade any shares of GNFTF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: